VYNE Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
09/06/2022 - 08:00 AM
September 13, 2022
BRIDGEWATER, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer of VYNE, is scheduled to participate at the H.C. Wainwright 24th Annual Global Investment Conference (Hybrid) on September 13, 2022. Management will also be available for one-on-one meetings with investors.
H.C. Wainwright 24th Annual Global Investment Conference – Presentation Details
Date: Tuesday, September 13, 2022 Time: 12:30 p.m. ET Format: Company Presentation Presenter: David Domzalski, President and Chief Executive Officer of VYNE Webcast Link: To attend, please register here . *a replay will be available on the VYNE website for 90 days following the presentation
Please contact your H.C. Wainwright & Co. representative if you would like to schedule a one-on-one meeting during the conference.
For more information about the H.C. Wainwright 24 th Annual Global Investment Conference , please refer to the conference website .
About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary bromodomain & extra-terminal (BET) domain platform includes lead programs VYN201 (pan-BETi) and VYN202 (selective-BETi), and access to a library of small molecule BET inhibitors for the potential treatment of immuno-inflammatory conditions licensed from Tay Therapeutics Limited.
For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com . VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.
Investor Relations: John Fraunces LifeSci Advisors, LLC 917-355-2395jfraunces@lifesciadvisors.com
Tyler Zeronda VYNE Therapeutics Inc. 908-458-9106Tyler.Zeronda@VYNEtx.com
VYNE Rankings
N/A Ranked by Stock Gains
VYNE Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
About VYNE
vyne therapeutics inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. it offers amzeeq, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. the company is also developing fmx103, which is in phase iii clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and fcd105, a topical combination foam that is in phase ii clinical trials for the treatment of moderate-to-severe acne vulgaris. in addition, it is developing serlopitant, a once-daily oral nk1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. the company was formerly known as menlo therapeutics inc. and changed its name to vyne therapeutics inc. in september 2020. vyne therapeutics inc. was founded in 2003 and is headquartered in bridgewater, new jersey.